within Pharmacolibrary.Drugs.ATC.N;

model N04BA02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Levodopa and decarboxylase inhibitor is a combination drug used in the management of Parkinson's disease. Levodopa is a precursor of dopamine, which is deficient in patients with Parkinson's disease, and the decarboxylase inhibitor (usually carbidopa) prevents the peripheral breakdown of levodopa, increasing its availability to the brain. This therapy is widely used and approved in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adults receiving single oral dose of levodopa/carbidopa (100 mg/25 mg).</p><h4>References</h4><ol><li><p>Tambasco, N, et al., &amp; Calabresi, P (2018). Levodopa in Parkinson&#x27;s Disease: Current Status and Future Developments. <i>Current neuropharmacology</i> 16(8) 1239–1252. DOI:<a href=&quot;https://doi.org/10.2174/1570159X15666170510143821&quot;>10.2174/1570159X15666170510143821</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28494719/&quot;>https://pubmed.ncbi.nlm.nih.gov/28494719</a></p></li><li><p>Müller, T (2020). Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson&#x27;s disease. <i>Expert opinion on drug metabolism &amp; toxicology</i> 16(5) 403–414. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2020.1750596&quot;>10.1080/17425255.2020.1750596</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32238065/&quot;>https://pubmed.ncbi.nlm.nih.gov/32238065</a></p></li><li><p>Tuunainen, J, et al., &amp; Yliperttula, M (2023). Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 48(1) 23–34. DOI:<a href=&quot;https://doi.org/10.1007/s13318-022-00800-w&quot;>10.1007/s13318-022-00800-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36309950/&quot;>https://pubmed.ncbi.nlm.nih.gov/36309950</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N04BA02_1;
